Brochure
12 Sep 2025

Dorra Product Lists

PDF 148 kB

Commercialized and Under-Development Pipline

Content provided by our supplier

Nanjing Dorra Pharmaceutical Technology Co.,Ltd.

  • Country/Region:
    China
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    50 - 99
Company types
CMO/CDMO
Licensee
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Animal Health
API Producer
Contract Manufacturer
Cosmetic Ingredients
Custom Manufacturing/Custom Synthesis
Excipients Manufacturer
Generic APIs producer
Intermediates Manufacturer
Natural Extracts
Supply Chain

Other Content from Nanjing Dorra Pharmaceutical Technology Co.,Ltd. (2)

  • News CEP of Fosfomycin Trometamol Newly Authorized!

    We are proud to announce that our Fosfomycin Trometamol API has officially received EU CEP certification (Certificate No. 2024-168-Rev00) from the EDQM.We warmly invite global partners to connect with us and explore new avenues for collaboration.
  • Video Company Video

    Dorrapharma is engaged in R&D, manufacture and market of intermediates, APls (Active Pharmaceutical Ingredients) and formulations. We own the core technology advantage in the professional area of bromination, enzyme/metal­catalyzed, nitration and hydrogenation, and obtain multiple core patents for invention. We stick to raising the value both for the company and customers, and devote ourselves completely to the technology innovation and brand build and make every effort to foster the core competence for the company with the company mission of a leading pharmaceutical integrated operator with its core competitive advantage in global market.